NCT06100315View on ClinicalTrials.gov

Nalbuphine as Adjuvant During Bilateral Suprazygomatic Maxillary Nerve Block for Pediatric Cleft Palate Repair

Active, not recruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Complication Following Peripheral Nerve Block
Interventions
DRUG

Nalbuphine

bupivacaine 0.125% of 0.2 ml/kg and 0.1 mg/kg nalbuphine

Trial Locations (1)

Unknown

Mohamed Fathy Mostafa, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT06100315 - Nalbuphine as Adjuvant During Bilateral Suprazygomatic Maxillary Nerve Block for Pediatric Cleft Palate Repair | Biotech Hunter | Biotech Hunter